Bardoxolone Metile ( DrugBank: Bardoxolone )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
67	Polycystic kidney disease	1

67. Polycystic kidney disease

---

Clinical trials : 221 /  Drugs : 212 - (DrugBank : 55) / Drug target genes : 40 - Drug target pathways : 151

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2018-004651-20-IT (EUCTR)	20/11/2019	05/01/2021	A Phase 3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients with Autosomal Dominant Polycystic Kidney Disease	A Phase 3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients with Autosomal Dominant Polycystic Kidney Disease - FALCON	Autosomal dominant polycystic kidney disease MedDRA version: 20.0;Level: LLT;Classification code 10036046;Term: Polycystic kidney, autosomal dominant;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]	Product Name: Bardoxolone methyl 5 mg Product Code: [RTA 402] INN or Proposed INN: Bardoxolone Metile Other descriptive name: Bardoxolone methyl Product Name: Bardoxolone methyl 10 mg Product Code: [RTA 402] INN or Proposed INN: bardoxolone methyl Other descriptive name: bardoxolone methyl Product Name: Bardoxolone methyl 20 mg Product Code: [RTA 402] INN or Proposed INN: Bardoxolone methyl Other descriptive name: Bardoxolone methyl Product Name: Bardoxolone methyl 15 mg Product Code: [RTA 402] INN or Proposed INN: Bardoxolone Methyl Other descriptive name: Bardoxolone methyl	REATA PHARMACEUTICALS, INC.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	300	Phase 3	France;United States;Czechia;Czech Republic;Spain;Belgium;Australia;Germany;United Kingdom;Italy